- SSB
sells and distributes Serratia marcescens nuclease worldwide
- Perfect
addition to SSB´s purification product portfolio
Sartorius
Stedim Biotech, a leading international pharma and biotech supplier, and
the biotechnology specialist c-LEcta, announce the signing of a
worldwide sales and distribution agreement for c-LEcta's proprietary
Serratia
marcescens nuclease for biopharmaceutical applications. The German company
specializes in the development of customized enzymes and production strains for
industrial applications. Based on this agreement, customized endonuclease will
now be available under the product name "Denarase" through all regular
Sartorius Stedim Biotech sales channels.
Endonucleases are used in various
biopharmaceutical production processes, such as in recombinant protein
production, to remove nucleic acids, reduce viscosity levels and thus optimize
process efficiencies. The company c-LEcta has optimized the production process
for
Serratia marcescens nuclease using a genetically engineered Bacillus
strain to increase enzyme activity yields and remove endotoxins. As a result,
this new technology enables the highest purity and quality nuclease to be
produced.
"This endonuclease provides outstanding
advantages from which our customers will benefit directly, such as cost
efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of
Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a
perfect addition to our current purification product portfolio and supports our
strategy as a total solution provider for the biopharmaceutical industry."
Dr. Marc Struhalla, Managing Director of
c-LEcta comments, "The technology developed by c-LEcta allows us to provide
nuclease to our customers in the highest quality. We are convinced that with
Sartorius Stedim Biotech, we have found the right sales and distribution
partner for the successful worldwide commercialization of our product."
About Sartorius
Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment
and services for the development, quality assurance and production processes of
the biopharmaceutical industry. Its integrated solutions covering fermentation,
cell cultivation, filtration, purification, fluid management and lab
technologies are supporting the biopharmaceutical industry around the world to
develop and produce drugs safely, timely and economically. Sartorius Stedim
Biotech focuses on single-use technologies and value-added services to meet the
rapidly changing technology requirements of the industry it serves. Strongly
rooted in the scientific community and closely allied with customers and
technology partners, the company is dedicated to its philosophy of "turning
science into solutions."
Headquartered in Aubagne,
France, Sartorius Stedim
Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing
and R&D sites in Europe, North America and Asia and
a global network of
sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key
manufacturing and R&D site is in Germany
. The company employs more than 2,800 people, and in 2011 earned sales revenue
of 477.3 million euros.
About c-LEcta GmbH
c-LEcta is a German biotechnology
company specializing in the development of customized enzymes and production
strains for industrial applications. Patented technologies are employed for
discovery and optimization of tailor-made enzymes and microbial strains.
c-LEcta's know-how in microbiology and strain engineering allows efficient
development of production strains for protein and small-molecule products.
Proprietary technologies are used for the identification of new enzymes from
biodiversity and for effective enzyme engineering.